Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMB920Z)

Drug Name
Ceritinib Drug Info
Synonyms
ceritinib; LDK378; 1032900-25-6; ZYKADIA; NVP-LDK378-NX; LDK-378; UNII-K418KG2GET; LDK378(Ceritinib); LDK 378; Eritinib (LDK378); 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine; K418KG2GET; CHEMBL2403108; CHEBI:78432; AK174337; ceritinib; C28H36ClN5O3S; 5-Chloro-N2-[2-isopropoxy-5-Methyl-4-(4-piperidyl)phenyl]-N4-(2-isopropylsulfonylphenyl)pyriMidine-2,4-diaMine; 5-Chloro-N2-(5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl)-N4-(2-(propane-2-sulfonyl)phenyl)pyrim
Cross-matching ID
PubChem CID
57379345
ChEBI ID
CHEMBL78432
CAS Number
CAS 1032900-25-6
TTD Drug ID
D04LVK
VARIDT Drug ID
DR00228
ACDINA Drug ID
D00115

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Steroid biosynthesis 2.48 0.00e+0 19/20 (95%) SQLE;MSMO1;LSS;...
Steroid hormone biosynthesis 2.42 0.00e+0 43/61 (70.49%) SRD5A1;AKR1C2;AKR1C1;...
PPAR signaling pathway 2.23 0.00e+0 66/74 (89.19%) HMGCS1;SCD;FADS2;...
Terpenoid backbone biosynthesis 2.16 0.00e+0 18/22 (81.82%) HMGCS1;IDI1;ACAT2;...
Fatty acid biosynthesis 1.90 9.70e-3 16/18 (88.89%) FASN;ACSL3;ACSL1;...
Ovarian steroidogenesis 1.89 8.08e-3 41/51 (80.39%) LDLR;HSD17B7;AKR1C3;...
Biosynthesis of unsaturated fatty acids 1.88 6.93e-3 21/27 (77.78%) SCD;ELOVL6;FADS2;...
Ascorbate and aldarate metabolism 1.82 1.62e-2 15/30 (50%) ALDH3A2;UGT2B28;UGT2B4;...
Metabolism of xenobiotics by cytochrome P450 1.81 1.62e-2 49/77 (63.64%) AKR1C1;EPHX1;ADH1B;...
Adipocytokine signaling pathway 1.76 2.34e-2 64/69 (92.75%) ACSL3;IRS2;NFKBIA;...
Fatty acid degradation 1.74 2.57e-2 40/43 (93.02%) ACAT2;ACSL3;ACSL1;...
Synthesis and degradation of ketone bodies 1.74 2.42e-2 9/10 (90%) HMGCS1;ACAT2
AMPK signaling pathway 1.71 3.11e-2 106/120 (88.33%) SCD;FASN;HMGCR;...
RNA transport -1.73 2.13e-2 128/186 (68.82%) RPP14;RPP30;NUP98;...
Dilated cardiomyopathy -1.74 1.95e-2 86/96 (89.58%) MYH7;GNAS;ATP2A1;...
Graft-versus-host disease -1.77 1.33e-2 32/42 (76.19%) KIR2DL3;HLA-E;HLA-C;...
Viral myocarditis -1.77 1.34e-2 53/60 (88.33%) ABL2;MYH6;CCND1;...
Amyotrophic lateral sclerosis -1.81 8.64e-3 267/364 (73.35%) COX6B1;NDUFB11;SDHD;...
Cell adhesion molecules -1.86 5.20e-3 118/148 (79.73%) CDH5;NLGN4X;HLA-DOA;...
Prion disease -1.89 4.54e-3 209/273 (76.56%) PSMD13;COX6A1;PSMA2;...
Hypertrophic cardiomyopathy -1.89 4.99e-3 81/90 (90%) EMD;PRKAA1;PRKAG1;...
Huntington disease -1.90 5.55e-3 233/306 (76.14%) ATG14;KCNJ10;SLC1A2;...
Type I diabetes mellitus -1.98 1.56e-3 38/43 (88.37%) HLA-E;HLA-C;PTPRN2;...
Cardiac muscle contraction -1.99 1.78e-3 64/87 (73.56%) CACNG4;COX6B1;TRDN;...
Autoimmune thyroid disease -1.99 2.08e-3 46/53 (86.79%) HLA-G;IFNA10;CD28;...
Proteasome -1.99 2.50e-3 44/46 (95.65%) PSMB7;PSMD14;PSMB8;...
Oxidative phosphorylation -2.01 3.12e-3 93/133 (69.92%) ATP4B;COX6A1;ATP5PO;...
Allograft rejection -2.10 4.16e-3 32/38 (84.21%) HLA-E;HLA-C;FAS;...
Parkinson disease -2.16 6.24e-3 176/249 (70.68%) PSMA3;NDUFB6;SEM1;...
Antigen processing and presentation -2.17 1.25e-2 60/78 (76.92%) HSPA1L;PSME1;KIR2DL3;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 0.12uM - 1.11uM 24H
TC-32 CVCL_7141 Homo sapiens 0.12uM - 1.11uM 24H
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.08uM - 10uM 6H, 24H, 48H
Brain
Glioblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-251 MG CVCL_0021 Homo sapiens 0.12uM - 1.11uM 24H
YH-13 CVCL_1800 Homo sapiens 0.12uM - 1.11uM 24H
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 0.12uM - 1.11uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.08uM - 10uM 6H, 24H, 48H
MDA-MB-468 CVCL_0419 Homo sapiens 0.12uM - 1.11uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BT-474 CVCL_0179 Homo sapiens 0.12uM - 10uM 24H
T-47D CVCL_0553 Homo sapiens 0.12uM - 1.11uM 24H
ZR-75-1 CVCL_0588 Homo sapiens 0.12uM - 1.11uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GP2d CVCL_1234 Homo sapiens 0.12uM - 1.11uM 24H
HT-29 CVCL_0320 Homo sapiens 0.12uM - 1.11uM 24H
SNU-407 CVCL_5004 Homo sapiens 0.12uM - 10uM 24H
Embryonic stem cell
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
WA09 (H9) Derived CVCL_9773 (WA09) Homo sapiens 0.08uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 0.12uM - 1.11uM 24H
HEC-151 CVCL_2927 Homo sapiens 0.12uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 0.12uM - 1.11uM 24H
HEC-251 CVCL_2928 Homo sapiens 0.12uM - 1.11uM 24H
HEC-265 CVCL_2929 Homo sapiens 0.12uM - 1.11uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 0.12uM - 1.11uM 24H
Kidney
Renal cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
RCC10RGB CVCL_1656 Homo sapiens 0.12uM - 1.11uM 24H
Rhabdoid tumor
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
G-401 CVCL_0270 Homo sapiens 0.12uM - 1.11uM 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 0.12uM - 1.11uM 24H
JHH-7 CVCL_1322 Homo sapiens 0.12uM - 1.11uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.08uM - 10uM 6H, 24H, 48H
NCI-H1437 CVCL_1472 Homo sapiens 0.12uM - 10uM 24H
NCI-H1573 CVCL_1483 Homo sapiens 0.12uM - 1.11uM 24H
NCI-H838 CVCL_1594 Homo sapiens 0.12uM - 1.11uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 0.12uM - 1.11uM 24H
HCC1588 CVCL_1263 Homo sapiens 0.12uM - 1.11uM 24H
HCC95 CVCL_1276 Homo sapiens 0.12uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H2110 CVCL_1529 Homo sapiens 0.12uM - 1.11uM 24H
NCI-H2172 CVCL_1534 Homo sapiens 0.12uM - 1.11uM 24H
Small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H841 CVCL_1595 Homo sapiens 0.12uM - 1.11uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 0.12uM - 1.11uM 24H
Oral cavity
Oral squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BICR 6 CVCL_1086 Homo sapiens 0.12uM - 10uM 24H
Ovary
Ovarian carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVK18 CVCL_1629 Homo sapiens 0.12uM - 1.11uM 24H
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ES-2 CVCL_3509 Homo sapiens 0.12uM - 1.11uM 24H
OVTOKO CVCL_3114 Homo sapiens 0.12uM - 10uM 24H
Ovarian cystadenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OAW 28 CVCL_1611 Homo sapiens 0.12uM - 10uM 24H
OC 316 CVCL_1615 Homo sapiens 0.12uM - 10uM 24H
Ovarian endometrioid carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
TOV-112D CVCL_3612 Homo sapiens 0.12uM - 1.11uM 24H
Ovarian granulosa cell tumor
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COV434 CVCL_2010 Homo sapiens 0.12uM - 1.11uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.12uM - 1.11uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 0.12uM - 1.11uM 24H
LNCaP clone FGC CVCL_1379 Homo sapiens 0.12uM - 1.11uM 24H
PC-3 CVCL_0035 Homo sapiens 0.12uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.12uM - 3.33uM 24H
IGR-37 CVCL_1303 Homo sapiens 0.12uM - 1.11uM 24H
Mel-HO CVCL_1402 Homo sapiens 0.12uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 0.12uM - 1.11uM 24H
SK-MEL-3 CVCL_0525 Homo sapiens 0.12uM - 10uM 24H
Stomach
Gastric adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
AGS CVCL_0139 Homo sapiens 0.12uM - 10uM 24H
MKN45 CVCL_0434 Homo sapiens 0.12uM - 1.11uM 24H
Gastric carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
IM95 CVCL_1305 Homo sapiens 0.12uM - 10uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 0.12uM - 1.11uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 0.12uM - 1.11uM 24H